joe iniowa

Long time investor, retired from tech space

[joe iniowa @Microcapreturns]

$GANX Gain Therapeutics. Good article. Only Parkinson’s drug in history to return smell/taste.

https://t.co/UN4eXrSede

https://t.co/6rKJS4NkPY

[Harmol Samra @HarmolSamra]

Today, @HostDigital_ ($HOST) announced a $15 million share buyback program.

Our share price hasn’t changed the power available at Site I or the signed 15-year take-or-pay lease behind it. Our top priority remains financing, developing, and delivering our contracted projects.

[joe iniowa @Microcapreturns]

@paytonandavadad It's a slide in their deck. It's nothing official. We also know they do not have the resources to run a phase 2.

[Harmol Samra @HarmolSamra]

A megawatt on paper doesn’t do much for anybody. A megawatt that’s energized, leased, financed, built, and collecting rent is what creates value per share. That's our focus at @HostDigital_. https://t.co/stigW8hyf1

[Coya Therapeutics @CoyaTx]

Coya today announced plans to initiate an open-label extension (OLE) of the Phase 2/3 ALSTARS Trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (#ALS).

We plan to initiate the OLE in response to requests from ALSTARS investigators and study participants. “The strong interest from investigators and participants in continuing treatment beyond the current 48-week study period underscores the importance of providing continued access to COYA 302 for eligible participants in the ALSTARS trial,” said Dr. Fred Grossman, DO, FAPA, our President and Chief Medical Officer.

For more details: https://t.co/FcS63nHjlk

#EndALS

[joe iniowa @Microcapreturns]

@genaue1263 @paytonandavadad As expected your that guy. I sold out so I am just going to post fake info over and over. Adios.

[joe iniowa @Microcapreturns]

$GANX First company to stop Parkinson’s progression. Historic data.

[Avid Trader @RealAvidTrader]

$GANX NEWS IS STUNNING
Stock Doesn’t Move…

“In the 12 evaluable participants, MDS-UPDRS motor scores were stable over the 12-month study period with rexaceract, demonstrating no clinically meaningful progression of motor symptoms”

🤯🤯🤯 READ THIS

https://t.co/1QX7OQgCBW

[joe iniowa @Microcapreturns]

@genaue1263 @paytonandavadad They are good for at least 6 months and have the ATM open that only needs 25k shares sold a day to keep them in excellent financial shape. When did you sell out?

[joe iniowa @Microcapreturns]

@genaue1263 @paytonandavadad So you sold out and now are bashing?

[joe iniowa @Microcapreturns]

@genaue1263 @paytonandavadad You think the XBI is a reflection of small biotech? Not in any way.

[joe iniowa @Microcapreturns]

@genaue1263 @paytonandavadad $GANX Gain Therapeutics has now shown after 360 days none of the patients showed Parkinson’s progression on the gold standard UPDRS scale. World first Parkinson’s modifying drug.

[joe iniowa @Microcapreturns]

@genaue1263 @paytonandavadad Did you sell your shares?

[joe iniowa @Microcapreturns]

@genaue1263 @parkinsonstory You should sell and move on. This is what Khalid said about the drug today. If anyone knows he knows. If you noticed nothing is moving in the small biotech space.

[joe iniowa @Microcapreturns]

@nigel_up_in_ya @parkinsonstory @AssadJason @PhilipEtienne No I do not believe they showed any other data than what was in the poster. I thought they would since they mentioned they were getting CSF data at 360 days. My guess not all reviewed and approved.

[joe iniowa @Microcapreturns]

@genaue1263 @parkinsonstory Roches deal is 5 to 10 years out. They might not even start a safety test for another year. Rexeceract can be helping patients in 2 years with the right big pharma. Isn't that what we all want? No drug has ever returned smell/taste and this one did it on 25% of patients in 90 day

[joe iniowa @Microcapreturns]

@genaue1263 @parkinsonstory They paid 100 m for a preclinical asset. They will have to pay 10x that for Gain and that's how they see it.

[joe iniowa @Microcapreturns]

@genaue1263 @parkinsonstory I don't think anyone can tell what's going inside the company unless you are an insider? Are you?

[joe iniowa @Microcapreturns]

$GANX Nice to see recognition of stable motor symptoms for Parkinson’s.

[Parkinson's News Today @parkinsonstory]

Explore the details: https://t.co/Hdz5YQ8YlB

Treatment with a newly named oral therapy for Parkinson's in a small early study led to stable motor symptoms for participants after one year.

#ParkinsonsDisease #PD #ParkinsonsNewsToday #Bionews

[joe iniowa @Microcapreturns]

$GANX Expecting additional 360 day data this week in addition to the UPDRS scores showing stable or improvement in Parkinson’s which is a world first accomplishment. Premeir International Conference starts today in Seoul Korea.

[Peter @benpieter001]

1/3 $GANX - Following my May review on GANX, herewith a new update with a somewhat evolved template, before the 7th of October presentation. So, actually I'm a bit too early, but I believe there is high likelyhood of a share price rerating. Do your own dd. Bullish on $GANX

happy reading!

note: this is my own research for my own portfolio. It suffers from all kinds of biases and convictions. written content is my own, but supported by ai agents for frequent bayesian scoring and report generation.